KOD logo

Kodiak Sciences (KOD) Company Overview

Profile

Full Name:

Kodiak Sciences Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

October 4, 2018

Indexes:

Not included

Description:

Kodiak Sciences Inc. is an independent biopharmaceutical company engaged in research, development, and commercialization of innovative biopharmaceutical drugs for the treatment of common eye diseases. Founded in June 2009, it is headquartered in Palo Alto, California. Kodiak Sciences Inc. does not have any developed drugs approved for commercial sale, and the company does not generate revenue from their sale. The company does not expect to generate revenue from sales until it completes development and clinical trials and receives regulatory approval for commercial sale of the developed drugs.

Events Calendar

Earnings

Next earnings date:

Mar 28, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Mar 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Feb 23, 2022

Analyst ratings

Recent major analysts updates

Dec 9, 24 Jefferies
Buy
Nov 15, 24 HC Wainwright & Co.
Neutral
Nov 15, 24 Barclays
Underweight
Sep 24, 24 HC Wainwright & Co.
Neutral
Sep 5, 24 HC Wainwright & Co.
Neutral
Apr 4, 24 UBS
Neutral
Apr 1, 24 Barclays
Underweight
Dec 21, 23 UBS
Neutral
Nov 17, 23 Capital One
Overweight
Jul 27, 23 UBS
Neutral

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025
Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025
Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025
KOD
prnewswire.comFebruary 4, 2025

PALO ALTO, Calif. , Feb. 4, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that senior management will present the Company's pipeline program exploring the treatment of glaucoma at the Glaucoma 360 New Horizons Forum 2025 on Friday, February 7, 2025, in San Francisco, CA.

KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates
KOD
zacks.comJanuary 6, 2025

Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases.

KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential
KOD
zacks.comDecember 10, 2024

Kodiak stock surges as Jefferies upgrades it to a "BUY" rating based on the significant potential of its pipeline candidates for retinal disease indications.

Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy?
Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy?
Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy?
KOD
zacks.comNovember 25, 2024

Kodiak Sciences Inc. (KOD) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, KOD's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Kodiak Sciences to Participate in Upcoming Investor Conferences
Kodiak Sciences to Participate in Upcoming Investor Conferences
Kodiak Sciences to Participate in Upcoming Investor Conferences
KOD
prnewswire.comNovember 11, 2024

PALO ALTO, Calif. , Nov. 11, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences.

Kodiak Sciences to Present at Innovate Retina 2024
Kodiak Sciences to Present at Innovate Retina 2024
Kodiak Sciences to Present at Innovate Retina 2024
KOD
https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-innovate-retina-2024-302275636.htmlOctober 14, 2024

PALO ALTO, Calif. , Oct. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today its participation in a presentation and panel at Innovate Retina 2024 on October 17, 2024, in Chicago, Illinois.

Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks
Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks
Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks
KOD
zacks.comOctober 10, 2024

KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory filing across three eye disease indications.

Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report?
Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report?
Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report?
KOD
zacks.comSeptember 13, 2024

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?

Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus
Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus
Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus
KOD
zacks.comAugust 16, 2024

Kodiak (KOD) reports a narrower-than-expected loss for the second quarter of 2024. The company provides updates regarding its pipeline development plans.

Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?
Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?
Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?
KOD
zacks.comJune 20, 2024

Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for Kodiak Sciences?
  • Does Kodiak Sciences pay dividends?
  • What sector is Kodiak Sciences in?
  • What industry is Kodiak Sciences in?
  • What country is Kodiak Sciences based in?
  • When did Kodiak Sciences go public?
  • Is Kodiak Sciences in the S&P 500?
  • Is Kodiak Sciences in the NASDAQ 100?
  • Is Kodiak Sciences in the Dow Jones?
  • When was Kodiak Sciences's last earnings report?
  • When does Kodiak Sciences report earnings?
  • Should I buy Kodiak Sciences stock now?

What is the ticker symbol for Kodiak Sciences?

The ticker symbol for Kodiak Sciences is NASDAQ:KOD

Does Kodiak Sciences pay dividends?

No, Kodiak Sciences does not pay dividends

What sector is Kodiak Sciences in?

Kodiak Sciences is in the Healthcare sector

What industry is Kodiak Sciences in?

Kodiak Sciences is in the Biotechnology industry

What country is Kodiak Sciences based in?

Kodiak Sciences is headquartered in United States

When did Kodiak Sciences go public?

Kodiak Sciences's initial public offering (IPO) was on October 4, 2018

Is Kodiak Sciences in the S&P 500?

No, Kodiak Sciences is not included in the S&P 500 index

Is Kodiak Sciences in the NASDAQ 100?

No, Kodiak Sciences is not included in the NASDAQ 100 index

Is Kodiak Sciences in the Dow Jones?

No, Kodiak Sciences is not included in the Dow Jones index

When was Kodiak Sciences's last earnings report?

Kodiak Sciences's most recent earnings report was on Nov 14, 2024

When does Kodiak Sciences report earnings?

The next expected earnings date for Kodiak Sciences is Mar 28, 2025

Should I buy Kodiak Sciences stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions